Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2017
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2017
SUMMARY
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Glutamyl Aminopeptidase - Pipeline Review, H2 2017, outlays comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Glutamyl aminopeptidase is an enzyme encoded by the ENPEP gene. It is a zinc-dependent membrane-bound aminopeptidase that catalyzes the cleavage of glutamatic and aspartatic amino acid residues from the N-terminus of polypeptides. The enzyme degrades vasoconstricting angiotensin II into angiotensin III and helps to regulate blood pressure. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Report covers products from therapy areas Cardiovascular, Oncology and Women's Health which include indications Hypertension, Congestive Heart Failure (Heart Failure), Endometriosis, Hepatic (Liver) Tumor, Idiopathic (Essential) Hypertension, Left Ventricular Dysfunction, Neuroblastoma and Resistant Hypertension.
Furthermore, this report also reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Glutamyl Aminopeptidase - Pipeline Review, H2 2017, outlays comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Glutamyl aminopeptidase is an enzyme encoded by the ENPEP gene. It is a zinc-dependent membrane-bound aminopeptidase that catalyzes the cleavage of glutamatic and aspartatic amino acid residues from the N-terminus of polypeptides. The enzyme degrades vasoconstricting angiotensin II into angiotensin III and helps to regulate blood pressure. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Report covers products from therapy areas Cardiovascular, Oncology and Women's Health which include indications Hypertension, Congestive Heart Failure (Heart Failure), Endometriosis, Hepatic (Liver) Tumor, Idiopathic (Essential) Hypertension, Left Ventricular Dysfunction, Neuroblastoma and Resistant Hypertension.
Furthermore, this report also reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
- The report reviews Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Overview
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Companies Involved in Therapeutics Development
APAvadis Biotechnologies Srl
Quantum Genomics SA
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Drug Profiles
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Product Development Milestones
Featured News & Press Releases
Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001
Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE
Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension
May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure
Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001
Feb 02, 2017: Quantum Genomics granted key European patent for QGC011 combination therapy program
Sep 29, 2016: Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
Sep 12, 2016: Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016
May 17, 2016: Quantum Genomics granted two new U.S. patents covering lead product QGC001
Feb 03, 2016: Quantum Genomics Expands U.S. Presence to Advance Its Development Programs for Cardiovascular Diseases
Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure
Sep 22, 2015: Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015
Mar 03, 2015: First patients recruited for Phase IIa trial of drug candidate QGC001
Jan 12, 2015: Quantum Genomics at J.P. Morgan 34th annual healthcare conference
Dec 11, 2014: Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Overview
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Companies Involved in Therapeutics Development
APAvadis Biotechnologies Srl
Quantum Genomics SA
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Drug Profiles
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Product Development Milestones
Featured News & Press Releases
Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001
Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE
Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension
May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure
Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001
Feb 02, 2017: Quantum Genomics granted key European patent for QGC011 combination therapy program
Sep 29, 2016: Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
Sep 12, 2016: Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016
May 17, 2016: Quantum Genomics granted two new U.S. patents covering lead product QGC001
Feb 03, 2016: Quantum Genomics Expands U.S. Presence to Advance Its Development Programs for Cardiovascular Diseases
Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure
Sep 22, 2015: Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015
Mar 03, 2015: First patients recruited for Phase IIa trial of drug candidate QGC001
Jan 12, 2015: Quantum Genomics at J.P. Morgan 34th annual healthcare conference
Dec 11, 2014: Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by APAvadis Biotechnologies Srl, H2 2017
Pipeline by Quantum Genomics SA, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by APAvadis Biotechnologies Srl, H2 2017
Pipeline by Quantum Genomics SA, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
APAvadis Biotechnologies Srl
Quantum Genomics SA
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
APAvadis Biotechnologies Srl
Quantum Genomics SA
